EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/ RITONAVIR +/- DASABUVIR FOR TREATMENT OF CHRONIC HCV INFECTION BY GENOTYPES 1 OR 4 IN MONO- AND HIV CO-INFECTED PATIENTS

Carmen HIDALGO-TENORIO; Samantha E. DE JESUS; Jose HERNANDEZ-QUERO; Antonio COLLADO; Javier DE LA TORRE; Miguel A. LOPEZ-RUZ; Rosario JAVIER-MARTINEZ; Leopoldo MUNOZ-MEDINA; Omar MOHAMED-OMAR; Federico GARCIA; Ana B. PEREZ; AND Juan PASQUAU

Volume : IX, Issue : II, February - 2019

EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/ RITONAVIR +/- DASABUVIR FOR TREATMENT OF CHRONIC HCV INFECTION BY GENOTYPES 1 OR 4 IN MONO- AND HIV CO-INFECTED PATIENTS

Carmen Hidalgo Tenorio, Samantha E. De Jesus, Jose Hernandez Quero, Antonio Collado, Javier De La Torre, Miguel A. Lopez Ruz, Rosario Javier Martinez, Leopoldo Munoz Medina, Omar Mohamed Omar, Federico Garcia, Ana B. Perez, And Juan Pasquau

Abstract :

Objectives: To analyze the effectiveness of ombitasvir–paritaprevir–ritonavir (OBV/PTV/rtv) with or without dasavubir(DSV) in a real–life cohort of patients with chronic HCV infection; to establish the influence of HIV coinfection on success rates; and to examine resistance mutations in patients with virological failure. Methods: Observational,retrospective,multi–centre study conducted in HCV patients who received OBV/PTV/rtv.The proportion of patients with undetectable HCV–RNA at 12 weeks after the end of treatment(SVR12) was calculated using modified intention–to–treat(mITT) and per–protocol(PP) analyses. Results: The study included 136 patients with median age of 51 years,63.2 % were coinfected with HIV;39.7 % had received previous antiviral treatment for HCV infection; 14.1% had cirrhosis;30.1 % were genotype 1a,39.7% genotype 1b and 25% genotype 4; 93.4% received OBV/PTV/rtv ± DSV for 12 weeks, 47.8% received this treatment plus ribavirin; 2.2% of patients discontinued the treatment. Effectiveness was 93.2 % by ITTm analysis and 96.1 % by PP analysis. These outcomes were not affected by coinfection with HIV (p=0.2). Virological failure was recorded in 4 patients (3.1%).Resistance mutations against NS5A were detected in three patients (75% of failures). Conclusions: These data confirm the high success rates reported by clinical trials for OBV/PTV/rtv plus DSV.Virological failure with OBV/PTV/rtv±DSV appears to mainly affect NS5A polymerase.